• Deracoxib Workflows for COX-2 and Canine Cancer

  2026-09-24

  Deracoxib offers a practical way to connect selective COX-2 inhibition with canine pain, inflammation, and tumor-cell assays. This workflow emphasizes concentration calibration, matched vehicle controls, and careful separation of combination effects from cell-type-specific toxicity.

• CGK733 in Ferroptosis Research: A Careful Framework

  2026-09-24

  Explore how CGK733 can be considered in ferroptosis research without conflating a research compound with evidence from a glioblastoma study. This article unpacks the study’s iron-homeostasis findings and outlines cautious, interpretable assay decisions.

• Separating Growth Arrest from Cell Death in Cancer Assays

  2026-09-23

  Hannah R. Schwartz’s dissertation argues that relative viability and fractional viability capture different parts of an anticancer response: changes in proliferation and the extent of cell killing. Its central practical message is to measure these outcomes separately and consider their timing, rather than treating a single viability readout as a complete account of drug activity.

• PRINT: RNA-Mediated Safe-Harbor Transgene Insertion

  2026-09-23

  The reference study introduces PRINT, an RNA-only strategy that uses eukaryotic R2 retroelement proteins to insert transgenes at a multicopy human safe-harbor locus. Its biochemical and cellular data show that target-primed reverse transcription can support efficient, site-directed insertion without donor DNA, while also identifying important constraints for junction validation, template design, and future transferability.

• Okadaic acid: PP1/PP2A Inhibition Workflow

  2026-09-22

  Okadaic acid (A4540) provides nanomolar inhibition of PP2A and PP1 for experiments that need controlled elevation of protein phosphorylation. It is suitable for biochemical phosphatase assays, apoptosis assay workflows, and phosphorylation-dependent signaling studies, but cellular concentrations, solvent effects, and apoptosis interpretation require empirical controls.

• Quercetin (N1841): Reliable Cell Assay Workflows

  2026-09-22

  A scenario-based guide to using Quercetin (SKU N1841) in cell viability, proliferation, and cytotoxicity workflows. It connects PI3K inhibition, mitochondrial apoptosis, assay optimization, data interpretation, and practical product-selection criteria.

• M344 Histone Deacetylase Inhibitor: Applied Lab Guide

  2026-09-21

  M344 is a cell-permeable histone deacetylase inhibitor for connecting chromatin acetylation with proliferation, differentiation, apoptosis, radiation response, and HIV-1 latency assays. This workflow emphasizes dose selection, time-resolved readouts, solubility control, and phenotype-specific troubleshooting.

• Viral RIPK3 Degradation Controls Inflammation

  2026-09-21

  The Immunity study identifies a cowpox virus and orthopoxvirus protein class that recruits the host SCF ubiquitin machinery to degrade RIPK3, a central necroptosis kinase. Its genetic and mouse experiments show that this viral strategy reshapes inflammation, viral replication, and mortality, revealing a direct connection between pathogen evolution and host cell-death control.

• Cy5 amine (non-sulfonated) Labeling Guide

  2026-09-20

  Cy5 amine (non-sulfonated), SKU A8143, provides a primary amine for covalent fluorescent labeling through compatible activated-ester, activated-carboxyl, or epoxide chemistry. It is suited to controlled mixed-solvent workflows for microscopy, flow cytometry, and biomolecule tracking, but its water insolubility makes it unsuitable for direct aqueous labeling and it is not intended for diagnostic or medical use.

• AZ505: Designing Better SMYD2 Inhibition Studies

  2026-09-19

  AZ505 is a substrate-competitive SMYD2 inhibitor for dissecting methyltransferase biology without directly competing with SAM. This guide connects biochemical selectivity, cellular assay design, and renal fibrosis evidence to improve interpretation in epigenetic regulation research and cancer biology research.

• Mycobacterium tuberculosis WecA: Kinetics and Assay Design

  2026-09-18

  Zhao and colleagues establish a practical expression, purification, and activity-analysis workflow for the difficult membrane enzyme WecA from Mycobacterium tuberculosis. Their use of Lemo21(DE3), T7-lysozyme regulation, mass-spectrometric protein identification, UMP-based product detection, and competitive inhibition analysis with tunicamycin provides a foundation for mechanistic studies and inhibitor screening.

• AAPH for Controlled Oxidative Stress Models

  2026-09-18

  AAPH offers a practical way to generate sustained peroxyl-radical stress for erythrocyte, protein, lipid, and antioxidant assays. This guide translates the 2024 hazelnut-protein study into executable workflows, comparison strategies, and troubleshooting decisions for reproducible in vitro experiments.

• SP2509: Reading LSD1 Biology Through Chromatin

  2026-09-17

  SP2509 is a potent Lysine-specific demethylase 1 antagonist for dissecting histone-dependent transcription in AML and cancer epigenetics. This article connects its biochemical activity with assay design and the chromatin insights gained from BRD4–RAC1 co-targeting research.

• SIRT1/2 Inhibitor IV: Causal Assay Strategy

  2026-09-17

  SIRT1/2 Inhibitor IV (cambinol) is a cell-permeable tool for dissecting SIRT1- and SIRT2-dependent signaling. This guide develops an evidence-aware assay strategy linking deacetylase perturbation with Ran lactylation, STAT3 transport, p53 acetylation, and tumor-model phenotypes.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-09-16

  The reference study identifies SMYD2 as a pharmacologically actionable regulator of cisplatin-induced renal fibrosis and inflammation. Using AZ505 and LLY507 in animal and tubular epithelial-cell models, the authors connect SMYD2 inhibition with reduced epithelial–mesenchymal transition, inflammatory signaling, and Smad3/STAT3 pathway activation.

8636 records 1/576 page Next 12345 下5页 Last page